argenxARGX
About: Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Employees: 1,148
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
126% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 34
107% more call options, than puts
Call options by funds: $375M | Put options by funds: $181M
22% more repeat investments, than reductions
Existing positions increased: 144 | Existing positions reduced: 118
11% more capital invested
Capital invested by funds: $19B [Q3] → $21B (+$2B) [Q4]
11% more funds holding
Funds holding: 352 [Q3] → 389 (+37) [Q4]
2.09% less ownership
Funds ownership: 58.62% [Q3] → 56.52% (-2.09%) [Q4]
10% less funds holding in top 10
Funds holding in top 10: 20 [Q3] → 18 (-2) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Guggenheim Yatin Suneja 30% 1-year accuracy 8 / 27 met price target | 82%upside $1,100 | Buy Maintained | 10 Mar 2025 |
Baird Joel Beatty 40% 1-year accuracy 17 / 43 met price target | 12%upside $680 | Neutral Maintained | 4 Mar 2025 |
Oppenheimer Leland Gershell 39% 1-year accuracy 22 / 56 met price target | 16%upside $704 | Outperform Maintained | 28 Feb 2025 |
Wells Fargo Derek Archila 40% 1-year accuracy 14 / 35 met price target | 22%upside $741 | Overweight Maintained | 28 Feb 2025 |
Citizens Capital Markets Jason Butler 37% 1-year accuracy 16 / 43 met price target | 16%upside $701 | Outperform Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 7 articles about ARGX published over the past 30 days









